iifl-logo

Strides Pharma Science Ltd Balance Sheet

649.9
(-0.31%)
Apr 30, 2025|03:53:33 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

FINANCIALS

Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

92.02

107.4

90.2

89.68

Preference Capital

0

0

0

0

Reserves

3,469.1

3,347.65

3,316.49

3,158.38

Net Worth

3,561.12

3,455.05

3,406.69

3,248.06

Minority Interest

Debt

1,649.79

1,414.2

1,283.92

917.46

Deferred Tax Liability Net

33.29

38.41

44.6

42.93

Total Liabilities

5,244.2

4,907.66

4,735.21

4,208.45

Fixed Assets

650.2

651.94

672.62

755.16

Intangible Assets

Investments

2,498.34

2,491.77

2,399.76

2,394.65

Deferred Tax Asset Net

124.78

133.65

122.18

118.14

Networking Capital

1,859.07

1,544.72

1,526.19

867.46

Inventories

470.18

490.76

513.06

689.08

Inventory Days

135.39

Sundry Debtors

1,508.51

1,307.78

1,296.32

821.67

Debtor Days

161.45

Other Current Assets

507.24

496.67

460.07

412.52

Sundry Creditors

-504.16

-643.44

-643.8

-762.96

Creditor Days

149.91

Other Current Liabilities

-122.7

-107.05

-99.46

-292.85

Cash

111.83

85.58

14.45

73.04

Total Assets

5,244.22

4,907.66

4,735.2

4,208.45

Strides Pharma : related Articles

Strides Pharma Q3 Profit at ₹90 Crore, Revenue Up 15%
31 Jan 2025|11:55 AM

EBITDA grew 48% YoY at ₹210 crore, from ₹142 crore in the same quarter last year, marking better profitability.

Read More
Strides Pharma Posts ₹93 Crore Q2 Profit
28 Oct 2024|05:13 PM

EBITDA rose significantly to ₹235.7 Crore, a 54% increase from ₹153 Crore in the corresponding period of the previous year.

Read More
Strides Pharma gets shareholders’ approval for CDMO unit
11 Sep 2024|03:17 PM

In September 2023, the pharmaceutical behemoth revealed OneSource. The stock exchanges approved the idea earlier this year, in May.

Read More
Strides gets US FDA nod for Theophylline tablets
6 Sep 2024|12:18 PM

The medication is bioequivalent and therapeutically equivalent to Schering Corp's Reference Listed Drug (RLD), THEO-DUR.

Read More
Strides Pharma's Chennai Facility Receives USFDA Approval
19 Aug 2024|03:21 PM

The Alathur facility is key to Strides' global operations, especially in the US and other regulated markets, specializing in the production of tablets and capsules.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.